This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: YM Bio, Exact, Peregrine

Cologuard is designed to detect altered genetic material in cells that are shed from the lining of the colon into stool from pre-cancerous and cancerous lesions. The Exact Sciences test can also detect blood in stool, which is another possible signal of colon cancer.

The more important and positive recent development was the release of new Cologuard validation data last month. Exact tweaked the biomarkers used in Cologuard resulting in higher sensitivities, particularly with pre-cancerous lesions and early-stage colon cancer. This is great news and bodes well for the ongoing pivotal validation study and the test's commercial potential.

The new validation data demonstrated 98% sensitivity for cancer and 59% sensitivity for advanced adenomas (pre-cancers) greater than or equal to 1 cm, at a specificity cut-off of 91%.

Sensitivity is the ability of a test to correctly identify a positive sample, i.e. if a person has a disease, how often does the test come back positive? Highly sensitive tests are good because they result in few false positives.

Exact wants Cologuard to be highly specific because that will cut down on the number of patients referred unnecessarily to colonoscopy. In other words, if Cologuard says a patient doesn't have colon cancer, it's very highly likely that colon cancer is not present. Fewer false positive results means fewer colonoscopies performed, which saves insurance companies money. In turn, insurers will actively encourage use of Cologuard and Exact can charge more for it.

Validation data presented in 2010 showed Cologuard to have 85% sensitivity for colon cancer and 64% sensitivity for pre-cancers. The latter number is higher than the new 59% sensitivity rate because lesions of 1 cm weren't included. When Exact applied the new, more rigorous pre-cancer standard to its 2010 samples, the sensitivity rate was 54%, so net, the newly tweaked Cologuard gained 5% improvement in sensitivity for pre-cancers.

A couple words of caution about the new Cologuard results: The data were obtained from 355 samples, so a smaller number than the 1,178 samples used to analyze the test in 2010. Also, the new samples come from patients referred after they underwent colonoscopies, which means the sensitivities could be artificially high. "Real world" samples would come from a pre-colonoscopy patient.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
EXAS $6.35 -9.16%
INCY $72.09 -3.05%
PPHM $0.35 -4.27%
SPPI $7.13 -2.26%
AAPL $95.18 1.64%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs